Completed PHASE3 INTERVENTIONAL 3-arm NCT00094757

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

A Multicenter, Randomized, Double-Blind Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Sponsor: Merck Sharp & Dohme LLC

Conditions Diabetes Mellitus, Type 2

Interventions Comparator: pioglitazone Comparator: placebo Comparator: sitagliptin 100 mg Comparator: sitagliptin 200 mg

Updated 8 times since 2017 Last updated: May 20, 2019 Started: Oct 6, 2004 Primary completion: Aug 17, 2005 Completion: Apr 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00094757, this PHASE3 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 8 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3
Jun 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jun 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.